EUVIMEDEUVIMED entdecken
Leserbrief

Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

Jia Jia, Lili Mao, Jing Lin, Wenyu Li, Pei Yuan, Lei Guo, Jie Dai, Caili Li, Xue Bai, Zhongwu Li, Yu Chen, Jun Guo und 2 weitere

Frontiers of Medicine · 2024

DOI: 10.1007/s11684-023-1046-2 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Frontiers of Medicine, 2024. Verfasst von Jia Jia und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospi…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Paget Disease, Extramammary, Immunoconjugates. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesPaget Disease, ExtramammaryImmunoconjugatesHumansFemaleMaleAgedAntibodies, Monoclonal, HumanizedMiddle AgedAntineoplastic Agents, ImmunologicalAged, 80 and over

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalERBB2 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Molecular Oncology, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Coll…
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
  • Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, 100142, China. silu15_silu@126.com.

Zitieren

APA

Jia, J., Mao, L., Lin, J., Li, W., Yuan, P., Guo, L., Dai, J., Li, C., Bai, X., Li, Z., Chen, Y., Guo, J., Ying, J., & Si, L. (2024). Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy. Frontiers of Medicine. https://doi.org/10.1007/s11684-023-1046-2

Vancouver

Jia J, Mao L, Lin J, Li W, Yuan P, Guo L, et al. Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy. Frontiers of Medicine. 2024. doi:10.1007/s11684-023-1046-2

BibTeX
@article{Jia2024,
  author = {Jia, Jia and Mao, Lili and Lin, Jing and Li, Wenyu and Yuan, Pei and Guo, Lei and Dai, Jie and Li, Caili and Bai, Xue and Li, Zhongwu and Chen, Yu and Guo, Jun and Ying, Jianming and Si, Lu},
  title = {Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy},
  journal = {Frontiers of Medicine},
  year = {2024},
  doi = {10.1007/s11684-023-1046-2}
}
Kostenlos starten →